Heather Wakelee, MD
Medical Oncology · Stanford, CANPI 1720137094
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Chugai Pharmaceutical Co., Ltd. at 50.2% of the total. 2025 is the largest year on record at $22,236, 2.2 times the $9,904 reported in 2019.
Across 82 payments — averaging $717.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chugai Pharmaceutical Co., Ltd.$30K
- AstraZeneca$4K
- Beone Medicines USA, Inc.$4K
- Novartis$4K
- F. Hoffmann-la Roche AG$3K
- Helsinn Healthcare SA$2K
- plus $11K from 12 others
Across 160 payments — averaging $12,955 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$903K
- Genentech, Inc.$660K
- Clovis Oncology, Inc.$101K
- Pfizer$89K
- Seagen Inc.$76K
- Helsinn Healthcare SA$60K
- plus $184K from 8 others
What the payments were for
- Consulting fees$33,63957%
- Speaking & faculty fees$3,5186%
- Travel & lodging$19,31633%
- Food & beverage$2,3434%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | 7 | $29,511 |
| AstraZeneca | 9 | $4,297 |
| Beone Medicines USA, Inc. | 3 | $4,125 |
| Novartis | 4 | $4,033 |
| F. Hoffmann-la Roche AG | 3 | $3,174 |
| Helsinn Healthcare SA | 2 | $2,363 |
| Daiichi Sankyo Inc. | 4 | $1,786 |
| GSK | 4 | $1,652 |
| Janssen Global Services, LLC | 1 | $1,550 |
| Pfizer | 15 | $1,509 |
| Astrazeneca UK Limited | 6 | $1,479 |
| Blueprint Medicines Corporation | 1 | $1,463 |
| Seagen Inc. | 13 | $1,167 |
| Genentech USA, Inc. | 3 | $298 |
| Genentech, Inc. | 1 | $187 |
| Merck | 4 | $141 |
| Johnson & Johnson | 1 | $71 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,834 in reported general payments places this provider in the 80th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 32 | $625,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $4,297 | $625,19432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 379 medical oncology providers in California.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.